Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently amended): A ~~Compounds~~ compound, including stereoisomers, of formula (I) ~~including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof~~



(I)

or a prodrug, or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed line may represent a double bond;

R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:
halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R_2, nitro, hydroxy, -NR_3R_4, cyano, and or a group Z;

R_1 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR_3R_4, or cyano;

R_2 is a C1-C4 alkyl, -OR_3, or –NR_3R_4;

R_3 is hydrogen or C1-C6 alkyl;

R_4 is hydrogen or C1-C6 alkyl;

R_5 is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR_3R_4[[;]], or -C(O)R_2;

R_6 is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR_3R_4[[;]], or -C(O)R_2;

R_7 is hydrogen, C1-C6 alkyl, halogen, [[or]] halo, or C1-C6 alkyl;

R_8 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_9 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{10} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{11} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{12} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{13} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{14} is R_3 or $-C(O)R_2$;

D is CR_8R_9 or is CR_8 when double bonded with G or A;

G is $CR_{10}R_{11}$ or is CR_{10} when double bonded with D or is CR_{10} when double bonded with X when X is carbon;

A is $CR_{12}R_{13}$ or is CR_{12} when double bonded with D;

X is carbon or nitrogen;

Y is nitrogen or $-CR_7$;

W is a 4-8 carbocyclic membered ring, which may be saturated or may contain one to three double bonds, and

in which:

- one carbon atom is replaced by a carbonyl or $S(O)_m$; and
- one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR_{14}, $S(O)_m$, carbonyl, and such ring may be further substituted by 1 to 8 R_6 groups;

Z is a 5-6 membered heterocycle or a phenyl, which may be substituted by 1 to 8 R_5 groups;

m is an integer from 0 to 2.

2. (Currently amended): A ~~Compounds~~ compound according to claim 1, in which W is selected ~~among~~ from the following groups:



in which:

W1 represents a 1,3-dihydro-2H-imidazol-2-one derivative;

W2 represents a imidazolidin-2-one derivative;

W3 represents a tetrahydropyrimidin-2(1H)-one derivative;
W4 represents a 2,5-dihydro-1,2,5-thiadiazole 1-oxide derivative;
W5 represents a 1,2,5-thiadiazolidine 1-oxide derivative;
W6 represents a 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide derivative;
W7 represents a 1,2,6-thiadiazinane 1-oxide derivative;
W8 represents a 1,2,6-thiadiazinane 1,1-dioxide derivative;
W9 represents a pyrrolidin-2-one derivative;
W10 represents a 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide derivative;
W11 represents a 1,3-oxazolidin-2-one derivative;
W12 represents a isothiazolidine 1,1-dioxide derivative;
W13 represents a 2(1H)-pyridinone derivative;
W14 represents a 3(2H)-pyridazinone;
W15 represents a 2,3-piperazinedione derivative;
and q is an integer from 0 to 4[[,]]; n is an integer from 0 to 6[[,]]; p is an integer from 0 to 3[[,]]; and m, R_6 and R_{14} are defined as in claim 1; or a prodrug, or a pharmaceutically acceptable salt or solvate thereof.

3. (Currently amended): A ~~Compounds~~ compound according to ~~claims~~ claim 1 ~~and 2~~ of formula (Ia), (Ib), (Ic), (Id), ~~and~~ or (Ie),



(Ia)



(Ib)



(Ic)



(Id)



(Ie)



(If)



(Ig)

in which R, R_1, Z, Y, W, A, D, G are defined as in claim 1 ~~and 2~~; or a prodrug, or a pharmaceutically acceptable salt or solvate thereof.

4. (Currently amended): A ~~Compounds~~ compound according to claim 1 ~~anyone of claims from 1 to 3~~, selected from the following group:

1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]-1*H*-pyrazol-3-yl}-2-imidazolidinone;
1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydro-4-quinazolinyl]-1*H*-pyrazol-3-yl}-2-imidazolidinone; and
1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl]-1*H*-pyrazol-3-yl}-2-imidazolidinone; or a prodrug, or a pharmaceutically acceptable salt or solvate thereof.

5. (Currently amended): A ~~Process~~ process for preparing a compound ~~compounds~~ of formula (Ia) comprising the following steps:



in which

step a stands for the nucleophilic substitution with a suitable amine ~~(such as a substituted aniline)~~ of compounds of formula (II), in basic conditions ~~(such as sodium hydride in a polar aprotic solvent)~~ to give compounds (III);

step b stands for the protection of the amino group with a suitable protecting group ~~(such as a BOC group)~~;

step c stands for the oxidation of the double bond with a suitable oxidizing agent ~~(such as ozone in a polar protic solvent)~~ to give the aldehyde of compounds (V);

step d + e stands for formation of the aldehyde group of compounds (VII) through formation of the enol ether by Wittig reaction in the usual conditions, followed by acid hydrolysis (step e);

step f stands for the reduction of the aldehyde group of compounds (VII) to the alcohol of compounds (VIII) with a suitable reducing agent ~~(such as sodium borohydride)~~;

step g stands for the conversion of the alcohol of compounds (VIII) into a suitable leaving group ~~(such as, for example, a halogen or reactive residue of sulphonic acid (e.g. mesylate, tosylate), preferably mesylate)~~;

step h stands for the deprotection of the amino group of compounds (IX);

step i stands for the intramolecular cyclization to give the cyclized compounds (X)

step j stands for conversion of the halogen derivative, preferably chloride, into compounds (Ia), by reaction with the suitable reactive -Z-W derivative, in basic conditions ~~(such as, for example, sodium hydride in a polar solvent)~~.

Claims 6-9 (Cancelled).

10. (Currently amended): A pharmaceutical composition comprising a compound of claim 1, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof ~~anyone from claim 1 to 4~~, in admixture with one or more physiologically acceptable carriers or excipients.

11. (Currently amended): A method for the treatment of ~~a mammal, including man, in particular in the treatment of~~ a condition ~~conditions~~ mediated by CRF (corticotropin-releasing factor), comprising administration of an effective amount of a compound according to claim 1, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof ~~any of claims from 1 to 4~~, to a mammal in need thereof.

12. (Currently amended): A method ~~according to claim 11,~~ in the treatment of depression and anxiety, comprising administration of an effective amount of a compound according to ~~any of claims 1 to 4~~ claim 1, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof.

13. (Currently amended): A method ~~according to claim 11~~, in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease), comprising administration of an effective amount of a compound according to ~~any of claims 1 to 4~~ claim 1, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof.